



## Corporate Profile

Illumina (NASDAQ: ILMN) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

## Contact Information

### For Company Information

Jacquie Ross  
Vice President, Investor Relations  
Illumina, Inc.  
**Phone:** 858.255.5243  
**E-mail:** [rchambers@illumina.com](mailto:rchambers@illumina.com)

### For Stock Based Inquiries

Computershare Trust Company, N.A.  
250 Royall Street  
Canton, MA 02021  
**Phone:** 800.251.4215  
**Corporate Website:** <http://www.computershare.com>

## Stock Performance

### ILMN (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$319.21</b>
Change (%)	<b>▲ 3.91 (1.24%)</b>
Volume	752,107
52 Week Low	\$225.82
Market Cap	\$46,923,870,000
Rolling EPS	5.56
PE Ratio	57.4119
Shares Outstanding	147,000,000
Data as of	03/21/19 4:00 p.m. ET



## Recent Headlines

Date	Title
02/28/19	Illumina to Webcast Upcoming Investor Conference Presentation
02/06/19	Illumina Names Susan E. Siegel to Its Board of Directors
01/29/19	Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2018
01/15/19	Illumina to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on Tuesday, January 29, 2019

## Events


There are currently no events scheduled.

## Analyst Coverage

Firm	Analyst
BANK OF AMERICA	DERIK de BRUIN
BARCLAYS	JACK MEEHAN
BTIG	DANE LEONE
CANTOR FITZGERALD	SUNG JI NAM
CITI	DAN ARIAS
COWEN AND COMPANY	DOUG SCHENKEL
CREDIT SUISSE	VAMIL DIVAN
FIRST ANALYSIS SECURITIES CORP	TRACY MARSHBANKS
GOLDMAN SACHS & CO.	ISAAC RO
ISI GROUP	ROSS MUKEN
J.P.MORGAN	TYCHO W. PETERSON
JANNEY CAPITAL MARKETS	PAUL KNIGHT
JMP SECURITIES	J.T. HARESCO
LEERINK SWANN LLC	DAN LEONARD
MAXIM GROUP	BRYAN BROKMEIER
MIZUHO SECURITIES	PETER LAWSON
MORGAN STANLEY	STEVE BEUCHAW
MORNINGSTAR INC.	CHARLIE MILLER
PIPER JAFFRAY	WILLIAM R. QUIRK
ROBERT W. BAIRD & CO., INC.	JEFFREY ELLIOT
STIFEL	MIROSLAVA MINKOVA
WEDBUSH SECURITIES	ZARAK KHURSHID
WELLS FARGO	TIM EVANS
WILLIAM BLAIR & COMPANY, LLC	AMANDA MURPHY

## Analyst Estimates / Ratings

Mean Recommendation: 1.9



Unable to fulfill request.

## Management

**Jay T. Flatley**  
Chief Executive Officer

**Francis deSouza**  
President

**Marc Stapley**  
Senior Vice President & Chief Financial Officer

**Paul Bianchi**  
Senior Vice President, Human Resources

**Charles Dadswell**  
Senior Vice President & General Counsel

**Christian Henry**  
Senior Vice President & Chief Commercial Officer

**Richard Klausner, M.D.**  
Senior Vice President & Chief Medical Officer

**Kirk Malloy, Ph.D.**  
Senior Vice President & General Manager, Life Sciences

**Nicholas Naclerio, Ph.D.**  
Senior Vice President, Corporate Development & General Manager, Enterprise Informatics

**Tina S. Nova, Ph.D.**  
Senior Vice President & General Manager, Oncology

**Tristan B. Orpin**  
Senior Vice President & General Manager, Reproductive and Genetic Health

**Matt Posard**  
Senior Vice President & General Manager, New and Emerging Market Opportunities

**Robert Ragusa**  
Senior Vice President, Global Quality and Operations

**Mostafa Ronaghi, Ph.D.**  
Senior Vice President & Chief Technology Officer

## Board of Directors

**William H. Rastetter, Ph.D.**  
Chairman

**Jay T. Flatley**

**Francis A. deSouza**

**Blaine Bowman**

**Daniel M. Bradbury**  
Director Since January 2004

**Karin Eastham**

**Robert S. Epstein, M.D.**

**Jeff Huber**

**Gerald Möller, Ph.D.**

**David R. Walt, Ph.D.**

**Roy Whitfield**

## SEC Filings

Company (Filer Name)	Filing Date	Form	Description
Illumina (deSouza Francis)	03/05/19	4	Statement of changes in beneficial ownership of securities
Illumina (EPSTEIN ROBERT S)	03/05/19	4	Statement of changes in beneficial ownership of securities
Illumina (Dadswell Charle)	03/05/19	4	Statement of changes in beneficial ownership of securities
Illumina (FLATLEY JAY T)	03/01/19	4	Statement of changes in beneficial ownership of securities

## Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	1,173	40,665.90	92.3	135,652,549
Mutual Fund	1,817	23,656.29	54.3	79,785,529
Insider *	20	185.92	0.5	661,696

\*Insider values reflect direct beneficial ownership.

## Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Baillie Gifford & Co.	16,078,282	10.9	-59,222	12/31/18
The Vanguard Group, Inc.	11,500,061	7.8	666,277	12/31/18
BlackRock Institutional Trust Company, N.A.	8,004,757	5.5	281,864	12/31/18
Capital Research Global Investors	6,083,291	4.1	-1,784,868	12/31/18
State Street Global Advisors (US)	5,795,367	3.9	64,990	12/31/18
Jennison Associates LLC	5,484,716	3.7	653,050	12/31/18
Edgewood Management LLC	4,092,184	2.8	-300,057	12/31/18
Capital International Investors	3,970,953	2.7	-68,814	12/31/18
Sands Capital Management, LLC	3,816,513	2.6	-186,658	12/31/18
Morgan Stanley Investment Management Inc. (US)	2,538,255	1.7	-203,405	12/31/18

Powered by **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed